Prana Biotechnology (Australia)

Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

Lars Lannfelt, Kaj Blennow, Henrik Zetterberg et al. · The Lancet Neurology · 2008 · 712 citations

Medicine, Neuroscience, Pharmacology +17

Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial Aβ

Paul A. Adlard, Robert A. Cherny, David I. Finkelstein et al. · Neuron · 2008 · 664 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses

Noel G. Faux, Craig Ritchie, Adam P. Gunn et al. · Journal of Alzheimer s Disease · 2010 · 395 citations · Full text

Medicine, Neuroscience, Pharmacology +17

The Alzheimer’s therapeutic PBT2 promotes amyloid‐β degradation and GSK3 phosphorylation via a metal chaperone activity

Peter J. Crouch, Maria S. Savva, Lin W. Hung et al. · Journal of Neurochemistry · 2011 · 178 citations

Life Sciences, Molecular Biology, Neuroscience +17

The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease

David I. Finkelstein, Jessica L. Billings, Paul A. Adlard et al. · Acta Neuropathologica Communications · 2017 · 100 citations · Full text

Medicine, Neuroscience, Pharmacology +17